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 DISCLAIMER 
 
This report is based on an assessment of the European HTA network EUnetHTA with the title “Ramucirumab in 
combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal 
junction carcinoma” published in March 2015. This short report was compiled by mainly using the information provided 
in the EUnetHTA assessment directly. Context-specific information for Austria on e.g. costs and epidemiologic data was 
incorporated whenever possible and further information on the included phase III study was added.   
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of Phar-
maceuticals was used for structuring this report [1]. The Model organises 
HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
Table 1: Research questions 
Element ID Research question 
B0001 What is ramucirumab and the comparators? 
B0002 What is the claimed benefit of ramucirumab in relation to the comparators? 
A0020 For which indications has ramucirumab received marketing authorisation? 
A0021 What is the reimbursement status of ramucirumab? 
A0002 What is the precise definition of advanced gastric cancer or gastro-oesophageal junction 
adenocarcinoma and which diagnosis is given according to ICD-10? 
A0004 What is the natural course of advanced gastric cancer or  
gastro-oesophageal junction adenocarcinoma? 
A0005 What are the symptoms and the burden of advanced gastric cancer or gastro-oesophageal junction 
adenocarcinoma for the patient? 
A0006 What is the burden of advanced gastric cancer or gastro-oesophageal junction adenocarcinoma  
for society? 
A0025 How is advanced gastric cancer or gastro-oesophageal junction adenocarcinoma currently 
managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
D0001 What is the effect on overall mortality of ramucirumab in combination with paclitaxel compared  
to other treatments in second-line therapy? 
D0005 How does ramucirumab in combination with paclitaxel affect symptoms and findings (severity, 
frequency) of patients with advanced gastric cancer or gastro-oesophageal junction 
adenocarcinoma compared to other treatments in second-line therapy? 
D0006 How does ramucirumab in combination with paclitaxel affect progression-free survival (PFS) of 
patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma compared to 
other treatments in second-line therapy? 
D0016 How does ramucirumab in combination with paclitaxel affect performance status, such as ECOG 
score, compared to other treatments in second-line therapy? 
D0012 What is the effect on health-related quality of life for ramucirumab in combination with paclitaxel 
compared to other treatments in second-line therapy? 
D0013 What is the effect on disease-specific quality of life for ramucirumab in combination with paclitaxel 
compared to other treatments in second-line therapy? 
C0008 How safe is the technology in relation to (the) comparator(s)? 
C0008a – What is the frequency of all adverse events with ramucirumab in combination with 
paclitaxel compared to other treatments in second-line therapy? 
C0008b – What is the frequency of discontinuation of treatment due to adverse events with 
ramucirumab in combination with paclitaxel compared to other treatments in second-line therapy? 
C0008c – What is the frequency of and what are the serious adverse events (SAEs) with 
ramucirumab in combination with paclitaxel compared to other treatments in second-line therapy? 
C0008d – What is the frequency of serious adverse events (SAEs) leading to death with 
ramucirumab in combination with paclitaxel compared to other treatments in second-line therapy? 
C0008e – What are the most frequent adverse events with ramucirumab in combination with 
paclitaxel compared to other treatments in second-line therapy? 
C0005 What are the susceptible patient groups that are more likely to be harmed with ramucirumab 
treatment in combination with paclitaxel? 
Horizon Scanning in Oncology 
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2 Drug description 
Generic/Brand name/ATC code:  
Ramucirumab/Cyramza
®
/LO1XC 
 
Developer/Company:  
Eli Lilly  
 
Description of the technology:  
Ramucirumab is a human immunoglobulin G1 (IgG1) monoclonal antibody 
produced in murine (NS0) cells by recombinant DNA technology. Vascular 
endothelial growth factor (VEGF) receptor 2 is the key mediator of VEGF in-
duced angiogenesis. Ramucirumab, is a human receptor-targeted antibody 
that specifically binds VEGF receptor 2 (VEGFR-2; the extracellular domain) 
and blocks binding of VEGF-A, VEGF-C, and VEGF-D, preventing the inter-
action of VEGF R2 with activating ligands (VEGF-A, VEGF-C, and VEGF-
D). As a result, ramucirumab inhibits ligand-stimulated activation of VEGF 
R2 and its downstream signalling components, including p44/p42 mitogen-
activated protein kinases, neutralising ligand-induced proliferation and mi-
gration of human endothelial cells [2, 3].  
The recommended dose of ramucirumab is 8 mg/kg on days 1 and 15 of a 28 
day cycle, prior to paclitaxel infusion. The recommended dose of paclitaxel 
is 80 mg/m
2
 administered by intravenous infusion over approximately 60 
minutes on days 1, 8 and 15 of a 28 day cycle. The recommended treatment 
duration is until disease progression or until unacceptable toxicity has oc-
curred. Prior to infusion of ramucirumab, a histamine H1 antagonist (e.g. di-
phenhydramine) should be administered. 
Rational multi-target approaches to angiogenesis are needed to overcome re-
sistance mechanisms. Inhibition of VEGFR-2 (or VEGF-A) may have some 
impact on these elements given pathway crosstalk, but is likely insufficient to 
prevent all escape mechanisms from occurring. Despite these potential mech-
anisms of resistance, ramucirumab may have distinct mechanistic advantages 
compared to other anti-angiogenic modalities.  Although a number of tyro-
sine kinase inhibitors are being used, their biochemical promiscuity and po-
tential for off-target toxicities present potential limitations in cancer therapy.  
Ramucirumab offers a novel mechanism for anti-angiogenic therapy with the 
potential for both high affinity and high specificity blockade of VEGFR-2. 
Because ramucirumab binds to VEGFR-2 specifically and with high affinity, 
it may offer a rational modulation advantage. In contrast to other agents di-
rected against the VEGFR-2/VEGF axis, ramucirumab binds a specific epi-
tope on the extracellular domain of VEGFR-2, thereby blocking all VEGF 
ligands from binding to this therapeutically validated target.  
Moreover, in contrast to bevacizumab, which binds to VEGF-A only, ramu-
cirumab blocks all known VEGFs from binding to VEGFR-2. The combined 
effects of high specificity and more complete target inhibition could lead to 
a more complete blockade of angiogenesis [15]. 
 
B0001:  
drug description 
recommended 
dosages 
B0002:  
claimed benefit of 
ramucirumab in 
relation to the 
comparators 
LBI-HTA | 2015 5 
3 Indication 
Ramucirumab in combination with paclitaxel is indicated for the treatment 
of adult patients with advanced gastric cancer or gastro-oesophageal junction 
(GEJ) adenocarcinoma with disease progression after prior platinum and flu-
oropyrimidine chemotherapy. According to treatment guidelines, only pa-
tients who have a good performance status at the time of progression after 
first-line treatment are considered to be candidates for second-line therapy 
(see Scope) [4]. 
 
 
 
4 Current regulatory status 
In Europe, ramucirumab received orphan drug status in 2012 and market 
authorization by the EMA in December 2014 [5]: 
 in combination with paclitaxel for the treatment of adult patients with 
advanced gastric cancer or GEJ adenocarcinoma with disease progres-
sion after prior platinum and fluoropyrimidine chemotherapy. 
 as monotherapy for the treatment of adult patients with advanced gas-
tric cancer or GEJ adenocarcinoma with disease progression after prior 
platinum or fluoropyrimidine chemotherapy, for whom treatment in 
combination with paclitaxel is not appropriate. 
In the US, the FDA granted market authorization for ramucirumab [6] 
 as a single agent or in combination with paclitaxel, for treatment of 
advanced gastric or gastro-esophageal junction adenocarcinoma, with 
disease progression on or after prior fluoropyrimidine- or platinum-
containing chemotherapy in April 2014. 
 in combination with docetaxel, for treatment of metastatic non-small 
cell lung cancer with disease progression on or after platinum-based 
chemotherapy. Patients with EGFR or ALK genomic tumour aberra-
tions should have disease progression on FDA – approved therapy for 
these aberrations prior to receiving Cyramza
®
 in December 2014. 
 in combination with FOLFIRI for the treatment of metastatic colo-
rectal cancer with disease progression on or after prior therapy with 
bevacizumab, oxaliplatin, and a fluoropyrimidine in April 2015. 
 
 
  
A0007:  
target population  
A0020:  
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5 Burden of disease 
Gastric cancers include malignancies that arise from the lining of the stom-
ach and the GEJ [7, 8]. Whereas stomach cancers occur in any part of the 
stomach, GEJ cancers occur “within 5 cm proximal and distal of the anatom-
ic cardia” [9]. The vast majority of gastric cancers are adenocarcinomas his-
topathological (about 90%), and in a minority of cases include lymphomas, 
gastrointestinal stromal tumours, or carcinoid tumours [7]. 
The commonly used Lauren classification of gastric adenocarcinoma defines 
2 subtypes, diffuse and intestinal, based on location and histopathological 
features [10, 11]. Diffuse cancers develop in the stomach wall and mucosa, 
usually in the distal part of the stomach and often in younger patients; they 
commonly metastasise to the peritoneum, and have a poor prognosis. Intes-
tinal-type adenocarcinomas are characterised by gland formation, and are mi-
croscopically similar to colonic mucosa and commonly affect older patients. 
Gland formation includes a range from well to poorly differentiated carcino-
mas, which grow by expansion, and not by infiltration [11, 12].  
Dietary (nitroso compounds, high salt diet with low vegetables) and lifestyle 
risk factors (smoking and alcohol consumption) account for one-third to one-
half of all gastric cancers. An important risk factor is H. pylori infection, es-
pecially certain genotypes (vacAs1-, vacAm1-, and cagA-positive). The risk is 
increased in hosts who possess specific types of cytokine polymorphisms (IL-
1B-511*T/*T or IL-1B-511*T/*C). Gastric ulcers, adenomatous polyps, and 
intestinal metaplasia have been associated with an increased risk of gastric 
cancer [13]. 
The symptoms and burden of advanced gastric cancer for the patient com-
monly include fatigue, nausea, vomiting, anorexia, abdominal pain, diarrhoea 
or constipation, melaena, haematemesis, weight loss, and anaemia [14-18] . 
In Western countries, 80% to 90% of patients with gastric cancer (in more 
than 90% adenocarcinomas) are either diagnosed at an advanced stage, when 
the tumour is inoperable and/or metastatic, or develop recurrence within 5 
years after initial surgery [19]. Patients who present with advanced gastric 
cancer at diagnosis have a poor prognosis and expected survival times of less 
than a year. They typically have lymph node metastases and surgery is not 
considered curative (but palliative if performed) [12, 19, 20]. The results of 
the EUROCARE-5 study showed that for patients diagnosed in 2000-2007 the 
European mean 5-year age-standardised relative survival for stomach cancer 
was 25.1% (95%CI 24.8% to 25.4%), the second lowest rate (after lung can-
cer) among all the common cancer sites studied [21]. The 5-year relative and 
period survival by stage was different for localised gastric cancer and that 
with distant metastases, namely 28.8% versus 4.2% [22].  
According to the EUCAN [23, 24] database, in 2012 the estimates of age-stand-
ardised (European) incidence rates (per 100,000) of gastric cancer (ICD C16) 
in men was 13.9 in Austria, the overall EU (27) rate being 15.2. The age-
standardised incidence rates of gastric cancer in 2012 in women was 7.3 in 
Austria, the overall EU (27) rate being 7.1. [23, 24]. 
In 2008, stomach cancer caused an estimated total loss of 378, 103, 197 and 
108 disability-adjusted life years (DALYs) per age- adjusted 100,000 popula-
tion in men in the Europe East, North, South and West WHO regions, respec-
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tively. For women the corresponding estimated losses were 185, 60, 107 and 
63 DALYs per age-adjusted 100,000 population [25]. 
Based on the estimated prevalence in the European countries of interest in 
the calendar year of 2011 the prevalence of gastric cancer, including GEJ 
cancer, was estimated to range from 2.8 to 3.6 per 10,000 in the EU commu-
nity. Based on an updated literature review conducted in October 2014 and 
indirect methods (estimation of gastric cancer prevalence as a function of in-
cidence and mean duration of disease) the population prevalence of gastric 
cancer (which includes GEJ cancer, as per ICD codes) in the European coun-
tries of interest (EU-28, plus Norway and Iceland) in the calendar year of 
2014, was estimated to range from 2.80 to 4.24 per 10,000 in the EU commu-
nity. This is below the threshold of 5 per 10,000 required by the European 
Commission for an orphan drug designation [26].  
 
 
 
6 Current treatment 
Most patients with advanced-stage disease will need palliative chemotherapy 
but not all patients receive first-line therapy; primarily because they are not 
considered fit enough to receive chemotherapy. According to the most cur-
rent ESMO-ESSO-ESTRO clinical practice guidelines [4] first-line palliative 
chemotherapy combination regimens based upon a platinum-fluoropyrimi-
dine doublet are generally used. Other doublet and triplet combinations are 
also sometimes used, including addition of an anthracycline (epirubicin) or 
a taxane (docetaxel). However, almost all patients with metastatic gastric can-
cer develop progressive disease after first-line therapy.  
With the availability of several active chemotherapy drugs, patients who re-
tain a good performance status after the initial treatment remain good can-
didates for additional therapy [27]. Relatively few patients in Western coun-
tries (approximately 15% to 50% of patients receiving first-line treatment) 
receive second-line treatment [28-30].  
In the EU there is currently no standard second-line treatment for patients 
with advanced gastric or GEJ adenocarcinoma following progression despite 
prior chemotherapy. According to the above mentioned ESMO-ESSO-
ESTRO guidelines, in patients of adequate performance status, second-line 
chemotherapy is associated with proven improvements in overall survival 
(OS) and quality of life (QoL) compared with best supportive care (BSC), 
with treatment options including irinotecan, docetaxel, or paclitaxel (Level 
of evidence I, Grade of recommendation A) [4].  
None of the 3 above-mentioned drugs is approved for second-line treatment 
but all are used off-label for patients with advanced disease whose cancer 
has progressed despite prior first-line chemotherapy. They are the most 
common agents recommended in treatment guidelines and the only agents 
listed in the most recent European ESMO-ESSO-ESTRO guidelines as 
second-line therapies, except when patients have a progression-free interval 
of >3 months after first-line therapy when patients could be re-challenged 
with first-line therapy [4]. According to the manufacturers’ file data 
paclitaxel and docetaxel are used in between 16% and 46%, irinotecan in be-
A0023:  
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tween 17% and 41% and BSC in between 15% and 37% of patients as a sec-
ond line treatment [26].  
Evidence supports the use of paclitaxel, in combination therapy, as reasona-
ble medical therapy at some point in the management of advanced gastric 
carcinoma. Paclitaxel monotherapy has demonstrated only minimal activity 
against gastric cancer. Paclitaxel plus radiation has shown some activity against 
gastric cancer [26, 31-35].  
In second-line clinical trials the following chemotherapy regimens have been 
used: irinotecan plus cisplatin or fluoropyrimidines; single-agent irinotecan; 
single-agent docetaxel; docetaxel plus oxaliplatin (expert opinion indicates 
that docetaxel is used more commonly with cisplatin or 5-fluorouracil [5-FU]); 
paclitaxel single-agent or plus platinum agents; and FOLFOX (folinic acid, 
5-FU, oxaliplatin) [36].  
Ramucirumab alone or in combination with paclitaxel is currently the only 
approved treatment option for patients with advanced disease whose cancer 
has progressed despite prior fluoropyrimidine and platinum chemotherapy, 
and for whom there are currently no standard therapies available. It is there-
fore already included in The National Comprehensive Cancer Network 
(NCCN) clinical practice guideline for gastric cancer [37]. 
Further treatment options include: palliative radiotherapy; endoscopic meth-
ods for relieving dysphagia such as oesophageal intubation, oesophageal di-
latation, brachytherapy and stents; laser therapy and stents; and palliative 
surgery – to bypass obstruction in patients with distal stomach cancers that 
are obstructing the passage of food out of the stomach [36]. 
 
 
 
7 Evidence 
3 sources of information, submitted by the marketing authorisation holder 
(MAH), were mainly used: the submission dossier, the draft and published 
European public assessment report (EPAR) for ramucirumab and a meta-
analysis report. The MAH performed a systematic literature search as a part 
of their submission dossier. They used a combination of subject terms and 
text words to define the population and all interventions and controls rele-
vant for this assessment, and searched in several relevant databases. The 
search strategy was adapted to each database. When necessary, additional non-
systematic searches were performed.  
The study types included in the clinical effectiveness and safety domains were 
limited to randomised controlled trials. The Cochrane risk of bias tool was 
used to assess the internal validity (see Risk of bias) and external validity was 
formally assessed only for direct evidence for the major outcomes. The evi-
dence was assessed as part of assessing the overall documentation for each 
outcome using GRADE (Grading of Recommendations, Assessment, Devel-
opment and Evaluation) (see Evidence profile). 
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The systematic search was undertaken initial in December 2013 and updat-
ed on 28 May 2014. For this report, a further update was conducted on 21 
August 2015. The search included subject headings and text words for the 
disease and the possible treatment, and run in:  
 Ovid MEDLINE(R) <1946 to August Week 2 2015>,  
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 
<August 20, 2015>, Ovid MEDLINE(R) Daily Update <August 20, 
2015>, Ovid OLDMEDLINE(R) <1946 to 1965> 
 EMBASE (via Elsevier) 
 The Cochrane Central Register of Controlled Trials  
(via The Cochrane Library) 
 Cochrane Database of Systematic Reviews  
(via The Cochrane Library) 
 Database of Abstracts of Reviews of Effects  
(via CRD, The Cochrane Library) 
 Health Technology Assessment Database  
(via CRD, The Cochrane Library) 
 NHS Economic Evaluation Database  
(via CRD, The Cochrane Library). 
The initial search identified 11,056 records via databases but only 43 remained 
after exclusion of duplicates and of studies that did not meet eligibility cri-
teria (based on title/abstract); additional publications were identified from 
conference abstracts and hand-searching. Finally 30 publications for 23 unique 
studies were identified but after limiting the focus to the intervention the 
included studies were reduced to only one study for direct evidence [38]. The 
update from August 2015 yielded 61 further references, but none met the in-
clusion criteria. Thus, only 1 phase III study was included.  
 
 
7.1 Efficacy and safety – Phase III studies 
Table 2: Summary of efficacy 
Study title  
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric  
or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial [38, 39] 
Study 
identifier 
NCT01170663, I4T-IE-JVBE, (IMCL CP12-0922) 
Design Phase 3, randomized, multicentre, placebo-controlled, double-blind study 
Duration  
of main phase 
Until PD, unacceptable toxicity, withdrawal of consent, or until other 
withdrawal criteria were met. 
Hypothesis Superiority 
Funding Eli Lilly and Company 
Treatment 
groups 
Ramucirumab + 
paclitaxel 
(n=330) 
Ramucirumab 8mg/kg on days 1 and 15 + paclitaxel 80mg/m
2 
on days 1, 8 
and 15 intravenous over app 60 minutes administered on a 28-day cycle 
Placebo + paclitaxel 
(n=335) 
Placebo + paclitaxel 80mg/m
2
 intravenous over approx. 60 minutes 
administered on a 28-day cycle. 
included:  
1 study for direct 
evidence  
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Endpoints and 
definitions 
Overall survival 
(primary outcome) 
OS Interval between date of randomization and the date of death  
from any cause. 
Progression-free 
survival 
PFS Time from the date of randomization until the date of objectively 
determined PD (RECIST 1.0) or death due to any cause, whichever 
was first.  
Overall response 
rate 
OR
R 
Proportion of patients achieving a best overall response of PR or CR.  
Patient-reported 
outcomes 
- Assessed using EORTC QLQ-C30 and EQ-5D-3L 
Safety - - 
Database lock 31 December 2012 
Results and analysis 
Analysis  
description 
Primary analysis 
ITT (cut-off date at 12 July 2013) (all randomized patients): 665 
Analysis  
population 
Inclusion  ≥ 18 years 
 Metastatic or non-resectable, locally advanced gastric or  
gastro-oesophageal junction adenocarcinoma; 
 Documented objective radiological or clinical disease progression during or 
within 4 months of the last dose of first-line platinum and fluoropyrimidine 
doublet with or without anthracycline;  
 ECOG performance status score of 0 or 1; 
 Measureable or non-measurable evaluable disease  
(defined with RECIST, version 1.1 
Exclusion  Squamous or undifferentiated gastric cancer; gastrointestinal perforation, 
fistulae, or any arterial thromboembolic event within 6 months 
 Any significant gastrointestinal bleeding or any significant venous 
thromboembolism within 3 months before randomisation; 
 Poorly controlled hypertension 
Characteristics  Ramucirumab 
+ paclitaxel 
Placebo + 
paclitaxel 
Age, years 
Median (range) 
< 65, % 
> 65, % 
 
61 (25-83) 
62 
38 
 
61 (24-84) 
63 
37 
Sex, % 
Male 
 
69 
 
73 
Ethnic origin (self-reported), % 
White 
Asian 
Black or other 
 
63 
33 
4 
 
59 
36 
4 
ECOG PS 
0 
1 
 
35 
65 
 
43 
57 
Site of primary tumor, % 
Gastric 
Gastro- oesophageal junction  
adenocarcinoma 
 
 
80 
20 
 
 
79 
21 
Disease, % 
Measurable 
Non-measurable 
 
81 
19 
 
81 
19 
Time to progressive disease on  
first-line therapy, % 
< 6 months 
≥ 6 months 
 
 
76 
24 
 
 
76 
24 
Disease progression  
during first-line therapy, % 
69 65 
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Analysis  
population 
(continuation) 
Characteristics 
(continuation) 
Tumor grade, % 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
Unknown or missing 
 
8 
29 
56 
6 
 
7 
32 
56 
6 
Histological subtype, %  
(Lauren classification) 
Intestinal 
Diffuse 
Mixed 
Unknown or not available 
 
 
44 
35 
6 
15 
 
 
40 
40 
4 
16 
Primary tumor present, % 63 62 
Number of metastatic Sites, % 
0-2 
≥ 3 
 
63 
37 
 
69 
31 
Peritoneal metastases, % 49 45 
Presence of ascites, % 
Yes 
No 
 
39 
61 
 
32 
68 
Weight loss (past 3 months) 
< 10% 
≥ 10% 
 
84 
16 
 
85 
14 
Previous treatment, % 
Triplet: platinum and fluoropyrimidine 
withanthracycline 
Doublet: platinum and fluoropyrimidine 
HER2, EGFR, or other 
 
23 
 
77 
9 
 
26 
 
73 
8 
Previous surgery for gastric cancer, % 
Yes 
Total gastrectomy 
Partial gastrectomy 
Other 
 
40 
16 
24 
<1 
 
38 
19 
18 
<1 
Descriptive 
statistics and 
estimated 
variability 
Treatment group Ramucirumab + paclitaxel Placebo + paclitaxel 
Number of subjects N = 330 N = 335 
Median OS, months 
95%CI for median 
9.6 
8.5 - 10.8 
7.4 
6.3 - 8.4 
Median PFS, months 
95%CI for median 
4.4 
4.2 - 5.3 
2.9 
2.8 - 3.0 
ORR, % 
95%CI 
27.9 
23.3 - 33.0 
16.1 
12.6 - 20.4 
Best overall response, % 
Complete response 
Partial response 
Stable disease 
Progressive disease 
Not evaluable or not 
assessed 
 
<1 
27 
52 
13 
7 
 
<1 
16 
47 
25 
12 
EQ-5D, mean (SD) 
Baseline index score 
End-of-treatment index score 
 
0·75 (0·22) 
0·61 (0·32) 
 
0·75 (0·24) 
0·60 (0·35) 
Horizon Scanning in Oncology 
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Effect estimate 
per 
comparison 
Comparison groups  Ramucirumab vs. Placebo 
OS HR (stratified) 0.807 
95%CI 0.678-0.962 
P value  0.0169 
PFS HR (stratified) 0.635 
95%CI 0.536-0.752 
P value <0.0001 
ORR Odds ratio 2.140 
95%CI 1.449, 3.160 
P value  0.0001 
Abbreviations: CI = confidence interval, CR = complete response, ECOG = Eastern Cooperative Oncology Group, EGFR = 
epidermal growth factor receptor, HER2 = human epidermal growth factor receptor 2, HR = hazard ratio, ITT = intention-
to-treat, ORR = overall response rate, OS = overall survival, PD = progressive disease, PFS = progression-free survival, 
PR = partial response, RECIST = Response Evaluation Criteria in Solid Tumors 
Table 3: Treatment-emergent AEs occurring in at least 10% of patients on ramucirumab plus paclitaxel,  
irrespective of causality 
Adverse events 
(according to NCI-
CTCAE; version 4.02) 
Ramucirumab + paclitaxel (n= 327) Placebo + paclitaxel (n= 329) 
Grade 1-
2, n (%) 
Grade 3, 
n (%) 
Grade 4, 
n (%) 
Grade 5, 
n (%) 
Grade 1-
2, n (%) 
Grade 3, 
n (%) 
Grade 4, 
n (%) 
Grade 5, 
n (%) 
Any patients with a 
treatment-emergent AE 
57 (17) 155 (47) 73 (22) 39 (12) 116 (35) 128 (39) 27 (8) 51 (16) 
Non-haematological AEs 
Fatigue 147 (45) 39 (12) 0 0 126 (38) 18 (5) 0 0 
Neuropathy 123 (38) 27 (8) 0 0 104 (32) 15 (5) 0 0 
Decreased appetite 121 (37) 10 (3) 0 0 92 (28) 13 (4) 0 0 
Abdominal pain 98 (30) 20 (6) 0 0 87 (26) 10 (3) 1 (<1) 0 
Nausea 109 (33) 5 (2) 1 (<1) 0 100 (30) 8 (2) 0 0 
Alopecia 107 (33) 0 0 0 126 (38) 1 (<1) 0 0 
Diarrhoea 94 (29) 12 (4) 0 0 71 (22) 4 (1) 1 (<1) 0 
Epistaxis 100 (31) 0 0 0 23 (7) 0 0 0 
Vomiting 78 (24) 9 (3) 1 (<1) 0 56 (17) 12 (4) 0 0 
Peripheral oedema 77 (24) 5 (2) 0 0 43 (13) 2 (<1) 0 0 
Hypertension 32 (10) 46 (14) 0 0 8 (2) 8 (2) 0 0 
Constipation 70 (21) 0 0 0 69 (21) 2 (<1) 0 0 
Stomatitis 62 (19) 2 (<1) 0 0 22 (7) 2 (<1) 0 0 
Pyrexia 56 (17) 3 (<1) 0 0 36 (11) 1 (<1) 0 0 
Proteinuria 50 (15) 4 (1) 0 0 20 (6) 0 0 0 
Malignant neoplasm 
progression 
5 (2) 16 (5) 4 (1) 27 (8) 1 (<1) 24 (7) 1 (<1) 34 (10) 
Weight decreased 39 (12) 6 (2) 0 0 45 (14) 4 (1) 0 0 
Dyspnoea 34 (10) 8 (2) 0 0 29 (9) 2 (<1) 0 0 
Rash 42 (13) 0 0 0 31 (9) 0 0 0 
Cough 40 (12) 0 0 0 25 (8) 0 0 0 
Back pain 35 (11) 4 (1) 0 0 35 (11) 5 (2) 0 0 
Hypoalbuminaemia 32 (10) 4 (1) 0 0 13 (4) 2 (<1) 0 1 (<1) 
Myalgia 34 (10) 0 0 0 32 (10) 1 (<1) 0 0 
Ascites 21 (6) 11 (3) 1 (<1) 0 14 (4) 13 (4) 0 0 
Headache 32 (10) 0 0 0 21 (6) 1 (<1) 0 0 
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Adverse events 
(according to NCI-
CTCAE; version 4.02) 
Ramucirumab + paclitaxel (n= 327) Placebo + paclitaxel (n= 329) 
Grade 1-
2, n (%) 
Grade 3, 
n (%) 
Grade 4, 
n (%) 
Grade 5, 
n (%) 
Grade 1-
2, n (%) 
Grade 3, 
n (%) 
Grade 4, 
n (%) 
Grade 5, 
n (%) 
Haematological AEs 
Neutropenia 45 (14) 71 (22) 62 (19) 0 40 (12) 51 (16) 11 (3) 0 
Anaemia 84 (26) 30 (9) 0 0 85 (26) 31 (9) 3 (<1) 0 
Leucopenia 54 (17) 52 (16) 5 (2) 0 47 (14) 19 (6) 3 (<1) 0 
Thrombocytopenia 38 (12) 5 (2) 0 0 14 (4) 6 (2) 0 0 
Abbreviations: AE = adverse event, NCI-CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events 
 
The RAINBOW [38] study is a global, multicentre, randomised, double-blind 
phase 3 study comparing the efficacy and safety of ramucirumab plus pacli-
taxel versus placebo plus paclitaxel in patients with metastatic gastric cancer 
or GEJ adenocarcinoma whose disease progressed while on or within 4 months 
after the last dose of standard first-line platinum- and fluoropyrimidine-based 
combination chemotherapy. All 665 patients were randomised in a ratio of 
1:1 to receive either ramucirumab plus paclitaxel or placebo plus paclitaxel. 
The primary endpoint in RAINBOW was OS, and the secondary endpoints 
included PFS, overall response rate (ORR), and QoL. Median duration of 
treatment with ramucirumab was 18 weeks (approximately 4 to 5 cycles) in 
the ramucirumab and paclitaxel group and 12 weeks in the placebo and pac-
litaxel group. Tumour assessments were made every 6 weeks. 
 
7.1.1 Effectiveness 
Ramucirumab plus paclitaxel reduced the risk of death from any cause by 
19% (HR= 0.81; 95%CI: 0.68 to 0.96; p=0.0169) compared with placebo plus 
paclitaxel. The study demonstrated a statistically significant improvement in 
OS, with an improvement in median survival of 2.27 months among patients 
treated with ramucirumab plus paclitaxel compared with those in the place-
bo plus paclitaxel group. Median OS was 9.63 (95%CI 8.6 to 10.8) months 
among patients treated with ramucirumab plus paclitaxel compared with 7.36 
(95%CI 6.3 to 8.4) months among those treated with placebo and paclitaxel 
(31% increase in survival time) [38].  
Treatment with ramucirumab plus paclitaxel significantly reduced the risk 
of disease progression or death (HR=0.64; 95%CI: 0.54-0.75; p<0.0001); the 
median progression-free survival (PFS) was 1.5 months longer in the ramu-
cirumab plus paclitaxel group compared with the placebo plus paclitaxel 
group. Median PFS in the ramucirumab plus paclitaxel group was 4.4 
(95%CI 4.2 to 5.3) months vs. 2.9 (95%CI 2.8 to 3.0) months in the placebo 
plus paclitaxel group.  
Information provided by the MAH [40] showed that a slightly greater pro-
portion of patients in the ramucirumab plus paclitaxel group compared 
with the placebo plus paclitaxel group experienced stability or improvement 
in symptoms such as fatigue (45% vs. 42%) and pain (56% vs. 49%). Slightly 
more patients reported better or stable physical functioning in the ramu-
cirumab plus paclitaxel group compared with the placebo plus paclitaxel 
group (56% vs. 47%). The results presented were collected after 6 weeks of 
treatment and are based on data collected from 75% of patients in the ra-
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mucirumab plus paclitaxel group and only 66% of patients in the placebo plus 
paclitaxel group.  
The results for overall response rate (ORR) are driven by the difference in par-
tial responses (28% in the ramucirumab plus paclitaxel group compared 
with 16% in the paclitaxel plus placebo group). Complete response was 
achieved only in less than 1% of patients in both groups (0.6% vs 0.3%).  
Activities of daily living were not assessed in the RAINBOW trial. Eastern 
Cooperative Oncology Group (ECOG) Performance Status (PS) was used as 
an approximation. The time to deterioration in ECOG PS assessed the risk 
of functional status worsening to the extent that patients were no longer able 
to work and may have been confined to bed for at least part of the day. 
Treatment with ramucirumab plus paclitaxel was associated with a delay in 
the time to worsening of functional status, as measured with the ECOG PS 
compared with treatment with placebo plus paclitaxel. The median time to 
deterioration, that is to ECOG PS=2 or higher was 10.0 months (95%CI 8.3 
to 15.0) in the ramucirumab plus paclitaxel group versus 8.6 months 
(95%CI 6.3 to 14.3) in the placebo plus paclitaxel group. The difference be-
tween the medians was 1.4 months (HR=0.798 (95%CI 0.612 to 1.040), 
p=0.094). The results are based on less than 50% of the patients from the 
RAINBOW study. 
Quality of life assessments were performed using the European Organisation 
for Research and Treatment of Cancer Quality of Life questionnaire (EORTC 
QLQ-C30) and the EuroQol five-dimensions, three-level scale (EQ-5D-3L).  
The EQ-5D quality of life questionnaire is a generic scale for assessing qual-
ity of life and incorporates five functional scales: mobility, self-care, usual ac-
tivities, pain/discomfort and anxiety/depression. The RAINBOW study pre-
sents limited EQ-5D-3L results [38], restricted to the data for baseline and 
for the end of treatment. The scale is from -0.59 to 1 with 1 representing per-
fect health [38].The EQ-5D-3L index scores were similar at baseline and at 
end of treatment. For the ramucirumab plus paclitaxel group mean at base-
line and end of treatment were (0.75 (SD 0.22) and 0.61 (SD 0.32) and for the 
placebo plus paclitaxel group 0.75 (SD 0.24) and 0.60 (SD 0.35). 
The EORTC quality of life questionnaire (QLQ) is an integrated system for 
assessing the health related QoL of cancer patients participating in interna-
tional clinical trials. The QLQ-C30 incorporates five functional scales (phys-
ical, role, cognitive, emotional, and social), three symptom scales (fatigue, 
pain, and nausea and vomiting), a global health status/QoL scale, and a num-
ber of single items assessing additional symptoms commonly reported by can-
cer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) 
and perceived financial impact of the disease. 
Patients in RAINBOW completed the EORTC QLQ-C30 (v3) at baseline, 
every 6 weeks from start to discontinuation. Time to deterioration (TtD) was 
defined as time from randomization to first worsening of ≥10 points (on 100-
point scale). In addition, scores were classified as improved or worsened if 
changed by ≥10 points relative to baseline, otherwise classified as stable. 
Based on results published as abstract and on information provided by the 
MAH, more patients in the ramucirumab plus paclitaxel group reported im-
proved or stable EORTC QLQ-C30 global health status compared with the 
placebo plus paclitaxel group at each visit during the treatment, mostly due 
to stabile status. By the end of treatment however a higher proportion of pa-
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tients in the placebo plus paclitaxel group had a stable or improved global 
health status (RR= 0.92 [95%CI 0.74 to 1.15]) [39, 41]. 
 
7.1.2 Safety 
In the RAINBOW trial most patients experienced adverse events (AEs), but 
there is no indication for a different frequency of AEs in patients treated 
with ramucirumab plus paclitaxel compared with placebo plus paclitaxel 
treatment, RR 1.01 (95%CI 0.99 to 1.03). Concerning AEs of grade 3 or 
higher, the RR is 1.30 (95%CI 1.18 to 1.44), which is a statistically significant 
difference in favour of the control group. 
The frequency of patients that discontinued treatment because of AEs was 
similar between patients treated with ramucirumab plus paclitaxel and pla-
cebo plus paclitaxel. Calculations based on the ITT population give an RR 
of 1.04 (95%CI 0.68 to 1.59).  
Treatment-emergent serious adverse events (SAEs) were reported for the time 
that patients were on the study drug and for 30 days after treatment. The time 
could be extended to include any time past treatment as long as the SAE was 
considered possibly, probably, or definitely related to study treatment by the 
investigator. The proportion of patients who experienced any SAE was simi-
lar among patients treated with ramucirumab plus paclitaxel and those treat-
ed with placebo plus paclitaxel. Based on the frequencies of SAE submitted 
by the MAH, an RR of 1.11 (95%CI 0.93 to 1.31) was calculated. Calculations 
based on selecting SAEs of grade 3 or above gave a similar result, RR 1.15 
(95%CI 0.95 to 1.38).  
The following SAEs occurred in 2% or more of patients receiving ramuciru-
mab plus paclitaxel and are listed in order of decreasing frequency: malignant 
neoplasm progression, neutropenia, abdominal pain, febrile neutropenia, gen-
eral physical health deterioration, anaemia, pyrexia and vomiting. The con-
trol calculation of risk ratio and 95%CI for the top 2 events at any grade gave 
an RR 0.89 (95%CI 0.60-1.33) for malignant neoplasm progression and RR 
4.02 (95%CI 1.15-14.13) for neutropenia (statistically significant in favour of 
the control group). 
The number of deaths due to an AE was similar in patients treated with ra-
mucirumab plus paclitaxel and those treated with placebo plus paclitaxel, 
13/327 (4%) vs. 15/329 (4.6%); RR 0.87 (95%CI 0.42 - 1.80) [26, 41]. This in-
cludes deaths due to AEs that occurred during treatment or up to 30 days af-
ter the last dose of study drugs. The numbers of patients with an AE leading 
to death are also reported to be 39/327 vs. 51/329, giving an RR of 0.77 (95%CI 
0.52-1.13) [26, 38]. Further, the numbers of deaths with a causal relationship 
to any study drug are reported as 6/327 vs. 5/329 patients for the ramuciru-
mab plus paclitaxel and placebo plus paclitaxel groups, respectively [33, 38]. 
The following AEs occurred in 10% or more of the patients in the ramuciru-
mab plus paclitaxel group, and based on the safety population (listed in or-
der of decreasing frequency): fatigue, neutropenia, neuropathy, decreased ap-
petite, abdominal pain, nausea, anaemia, leukopenia, alopecia, diarrhoea, epi-
staxis, vomiting, oedema peripheral, hypertension, constipation, asthenia, 
stomatitis, pyrexia, proteinuria, malignant neoplasm progression, peripheral 
neuropathy, weight decrease, thrombocytopenia, dyspnoea, cough, back pain, 
rash, hypoalbuminaemia, myalgia and ascites [26, 38]. 
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The draft EPAR stated that no studies were conducted in special popula-
tions [3]. The submission dossier does comment on whether there is a need 
to optimise the use of the technology, or monitor the use of the technology to 
minimise the potential risks to safety. Labelling for ramucirumab will in-
clude the following warnings and precautions; arterial thromboembolism, 
hypertension, infusion related reactions, gastrointestinal perforation, severe 
bleeding, impaired wound healing, and hepatic impairment and severe gas-
trointestinal haemorrhage. If patients are predisposed towards any of these 
events, they may be more likely to be harmed. Wound healing and changes 
in the blood and lymphatic systems may be of importance if emergency op-
erations are necessary. As far as possible, this will be handled by the warn-
ing statements and the fact that the drug can be prescribed only by doctors 
experienced in oncology [2].  
In addition, the draft EPAR states that data on VEGF over-expression was 
not collected during the RAINBOW trial [3]. Based on data from the RE-
GARD trial of ramucirumab monotherapy it appeared that those with high-
er VEGFR-2 neoplastic vessel staining may have better OS and/or PFS. How-
ever, this was mainly due to differences in the placebo group, so it may be a 
prognostic factor [3]. 
The draft EPAR also comments on the issue that with both treatment alter-
natives in the RAINBOW study, patients with a previous history of hyper-
tension had an increased incidence of grade 3 or higher hypertension, older 
patients had an increased incidence of grade 3 or higher neutropenia, and 
Asian patients had an increased incidence of grade 3 or higher neutropenia 
and leukopenia. In view of these findings it is not possible to attribute the in-
creased risk to ramucirumab, but these risk factors are still issues that could 
be considered when selecting treatment for individuals.  
 
 
 
8 Estimated costs 
In Austria, one 50ml vial Cyramza
® 
containing 500 mg ramucirumab costs 
€ 3,131 and one vial containing 100 mg costs € 651 [42]. Assuming an aver-
age body weight of 70kg, 560 mg are needed. Thus 1 vial each would be need-
ed, resulting in costs of € 3,781 per day and in monthly costs of € 7,562 when 
ramucirumab is administered every two weeks.  
 
 
 
9 Ongoing research 
No planned or ongoing RCT of ramucirumab in combination with paclitaxel 
was identified. One ongoing phase III study (the REGARD trial) for stom-
ach cancer was found, investigating ramucirumab monotherapy for the sec-
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ond-line therapy of adenocarcinomas of the stomach or GEJ (NCT00917384: 
estimated study completion date: June 2015).  
5 planned, ongoing or unpublished studies using ramucirumab in patients 
with gastric cancer and/or GEJ adenocarcinoma were also found: 4 were non-
randomised open- label studies and in the EPAR a study called “I4T-MC-
JVDD: Safety and Effectiveness of Ramucirumab in Patients with Advanced 
Gastric Cancer in the European Union and North America: A Prospective 
Observational Registry” is mentioned. The final study report is estimated 
for completion in Q4 2021 [41].  
Ramucirumab is also under investigation in phase III trials for other types 
of cancer such as non-small cell lung cancer, hepatocellular carcinoma and 
breast cancer. 
 
 
 
10 Commentary 
Particularly in Western countries, where up to 90% of patients with gastric 
or GEJ adenocarcinoma are diagnosed at an advanced stage, the prognosis re-
mains poor despite some progress in the treatment of gastric cancer. Currently 
in the EU there is no standard second-line treatment for patients with ad-
vanced gastric or GEJ adenocarcinoma following progression after first-line 
chemotherapy and ramucirumab alone or in combination with paclitaxel is 
the only approved treatment option for these patients. 
The direct evidence for ramucirumab plus paclitaxel is based on one random-
ised controlled trial with a low risk of bias (RAINBOW study [38]). Even 
though other drugs currently available (docetaxel, irinotecan, paclitaxel) are 
used as off-label second-line therapy, paclitaxel seems an appropriate choice 
for the control group of the RAINBOW trial since paclitaxel had been shown 
to have similar activity to other single-agent (including docetaxel and irinotec-
an) or combination chemotherapy regimens in off-label use in second-line 
treatment of advanced gastric cancer. 
RAINBOW is the largest clinical trial of second-line therapy in this patient 
population to date. The demographic, disease, and other baseline character-
istics (ECOG PS; age; previous treatment) reflect a typical clinical trial pop-
ulation of advanced gastric cancer patients and are largely representative of 
the target patient population.  
The primary endpoint of improved OS was met in addition to improvements 
in PFS, while maintaining QoL. The robustness of the OS and PFS results 
was supported by sensitivity analyses. However, defining the size of clinical-
ly meaningful outcomes is challenging. There are no published recommen-
dations for what effect size on OS or PFS is acceptable as clinically meaning-
ful for this particular patient population, even though the topic has been dis-
cussed for example by the American Society of Oncology (ASCO). The dif-
ference of approximately 2 months in median OS achieved in RAINBOW 
seems a good result in this poor-prognosis population since patients whose 
disease progresses after first-line treatment can expect median survival un-
der 6 months. Results in secondary endpoints such as PFS and objective re-
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sponse rate supported the observed improvement in OS. QoL was maintained 
for a longer duration in the ramucirumab plus paclitaxel arm with more pa-
tients reporting stable or improved QoL. However, differences in quality of 
life between the treatment groups were small and may indicate that ramu-
cirumab plus paclitaxel does not impose an extra burden on the patients com-
pared with paclitaxel treatment. 
Nearly all patients with ramucirumab plus paclitaxel with placebo plus pac-
litaxel experienced an AE. There were no statistically significant differences 
between the treatments. However, limiting the AEs to those of grade 3 add-
ing ramucirumab increased the risk from 626 per 1,000 treated to 814 
(95%CI 739 to 902), which some may find clinically important. We did not 
find differences between the groups in withdrawal due to AEs, frequency of 
SAEs or AEs leading to death. The evidence suggests that the addition of 
ramucirumab to paclitaxel did not add to the burden of treatment in an 
unmanageable way. Finally, caution is needed, because the results are based 
on only one study.  
The study itself, RAINBOW [38], has a low risk of bias and high internal va-
lidity (see Risk of bias), but its external validity is more uncertain. In addition, 
for some outcomes there are few events, resulting in wide confidence inter-
vals. The quality of the evidence is considered moderate according to GRADE 
because it was limited to only one clinical study (details of individual GRADE 
assessments are shown in the Evidence profile). 
There is no direct head-to-head evidence to position ramucirumab plus pac-
litaxel compared with the other treatment alternatives used in second-line 
treatment of advanced gastric cancer or GEJ adenocarcinoma - except for 
paclitaxel alone. Direct comparisons and large observational studies and data 
are thus needed to facilitate more robust conclusions. Upcoming evidence 
from registries will provide results that should help to clarify these issues. 
The RAINBOW study included patients with ECOG PS 0 and 1. For patient 
with performance status worse than 1, efficacy data are not available.  
In the absence of clear signals against the generalizability of results, the 
CHMP concluded against a restriction of the indication to patients with good 
performance status. Use in a substantially larger patient population, and per-
haps in a more heterogeneous patient group with more comorbidities could 
lead to the discovery of additional AEs or changes in the expected frequen-
cies. Ramucirumab has a risk management plan, a pharmacovigilance plan 
and a risk minimisation plan. This includes a large observational study to 
collect systematically additional data from real-life use.  
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Appendix 
Scope 
Table 4: Inclusion criteria 
Description Project Scope  
Population Adults with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma 
previously treated with chemotherapy and with good performance status  
(Eastern Cooperative Oncology Group [ECOG] score of 0 or 1). 
International Classification of diseases (ICD)-10 code: C 16; C16.0 
MeSH-terms: stomach neoplasms; esophageal neoplasms or non-MeSH term gastro 
oesophageal junction adenocarcinoma 
Intervention  Ramucirumab in combination with paclitaxel (as second- line therapy). 
Ramucirumab is not yet mapped as a MeSH term.  
Alternative MeSH terms: antineoplastic agents; antibodies; submapped to:  
antibodies, monoclonal; or non-MeSH term ramucirumab 
Comparison  Docetaxel monotherapy 
 Paclitaxel monotherapy  
 Irinotecan monotherapy 
 Best supportive care 
At present there are no other technologies (pharmaceuticals) than ramucirumab with 
marketing authorisation for the intended patient population. The off-label comparators 
were chosen based on information in published guidelines  
[ESMO-ESSO-ESTRO, 2013; EUnetHTA, 2013]  
MeSH terms: antineoplastic agents; taxoids; paclitaxel; antineoplastic agents, 
phytogenic; or non-MeSH term docetaxel; irinotecan; best supportive care. 
Outcomes Efficacy 
 Overall survival (OS);  
 Progression-free survival (PFS);  
 Objective response rate (ORR);  
 Health-related quality of life (HRQoL); 
Safety 
 Adverse events (AEs) of treatment (Any AEs, serious AE [SAE], discontinuation  
due to AE, AE of special interest, most frequent, death as SAE)  
 Rationale for choosing the outcomes: commonly used outcomes in cancer studies 
and outcomes important for relative effectiveness assessment;  
based on recommendations from the EUnetHTA methods guideline on clinical  
and surrogate endpoints and safety.  
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Risk of bias 
Table 5: Risk of bias – study level 
Trial 
Adequate 
generation of 
randomisation 
sequence 
Adequate 
allocation 
concealment 
Blinding Selective 
outcome 
reporting 
unlikely 
No other 
aspects which 
increase the 
risk of bias 
Risk of bias – 
study level Patient 
Medicinal 
personnel and 
other staff 
RAINBOW (I4T-IE-JVBE/IMCL CP12- 0922)  Yes Yes Yes Yes Yes Yes Low 
 
Table 6: Risk of bias – outcome level  
Outcome 
Trial 
Blinding –  
outcome assessors 
ITT principle  
adequately realized 
Selective outcome 
reporting unlikely 
No other aspects 
according to risk of 
bias 
Risk of bias –  
outcome level 
Overall survival (OS) 
RAINBOW Low Low Low Low Low 
Progression free survival (PFS) 
RAINBOW Low Low Low Low Low 
Objective response rate (ORR) 
RAINBOW Low Low Low Low Low 
Health-related quality of life (HRQoL) 
RAINBOW Low Low Low Low Low 
Adverse events 
RAINBOW Low Low
0
 Low Low Low 
comments: 0: Adverse events was reported for the safety population (all patients that received at least one dose of any study drug) instead of all randomised patients  
 
 
 
 
Horizon Scanning in Oncology 
24 LBI-HTA | 2013 
Evidence profile 
The external validity was assessed using GRADE  
(Grading of Recommendations, Assessment, Development and Evaluation, 
www.gradeworkinggroup.org) only for the following outcomes:  
OS, PFS, QoL of direct evidence. The GRADE method involves an evaluation 
of factors influencing our confidence in the reported estimates. It includes 
an evaluation of study type, study quality (risk of bias), consistency of results 
between trials, directness (how similar the population, intervention, and out-
comes are among the trials and the objectives of this report), precision of the 
estimates and publication bias. GRADE may also take into account whether 
there are strong associations between the intervention and the outcome such 
as a very large effect, whether there are dose-response associations or wheth-
er all confounding variables would have reduced the effect. Results are as far 
as possible presented as absolute and relative terms. Finally, the overall quali-
ty, or confidence in the estimate, was categorised as high, moderate, low or 
very low. 
The categories should be interpreted as follows:  
 High quality: We are very confident that the true effect lies close to 
that of the estimate of the effect 
 Moderate quality: We are moderately confident in the effect estimate: 
the true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different 
 Low quality: Confidence in the effect estimate is limited: the true ef-
fect may be substantially different from the estimate of the effect 
 Very low quality: We have very little confidence in the effect estimate: 
the true effect is likely to be substantially different from the estimate 
of the effect. 
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Table 7: GRADE evidence profile for direct evidence and effectiveness outcomes 
Quality assessment № of patients Effect 
Quality № of 
studies 
Study  
design 
Risk  
of bias Inconsistency Indirectness Imprecision 
Other 
considerations 
ramucirumab  
+ paclitaxel 
placebo + 
paclitaxel 
Relative 
(95%CI) 
Absolute 
(95%CI) 
Mortality 
1  randomised 
trials  
not 
serious  
serious
1
 not  
serious  
not  
serious  
none  256/330 
(77.6%)  
260/335 
(77.6%)  
HR 0.807 
(0.678 to 
0.962)  
75 fewer per 1000 
(from 13 fewer to 139 
fewer)  
⨁⨁⨁ 
MODERATE  
Patients with progression 
1  randomised 
trials  
not 
serious  
serious
1
 not  
serious  
not  
serious  
none  279/330 
(84.5%)  
296/335 
(88.4%)  
HR 0.635 
(0.536 to 
0.752)  
139 fewer per 1000 
(from 82 fewer to 199 
fewer)  
⨁⨁⨁ 
MODERATE  
Median survival 
1  randomised 
trials  
not 
serious  
serious
1
 not  
serious  
not  
serious  
none  330  335  - median 9.63 higher 
(8.48 higher to 10.81 
higher)  
⨁⨁⨁ 
MODERATE  
Objective response rate (ORR) (assessed with: complete or partial response) 
1  randomised 
trials  
not 
serious  
serious
1
 not  
serious  
not  
serious  
none  92/330  
(27.9%)  
54/335 
(16.1%)  
OR 2.14 
(1.45 to 
3.16)  
130 more per 1000 
(from 57 more to 217 
more)  
⨁⨁⨁ 
MODERATE  
Quality of Life (end of treatment) (assessed with: EORTC QLQ-C30) 
1  randomised 
trials  
not 
serious  
serious
1
 not  
serious  
not  
serious  
none  101/330 
(30.6%)  
111/335 
(33.1%)  
RR 0.92 
(0.74 to 
1.15)  
27 fewer per 1000 
(from 50 more to 86 
fewer)  
⨁⨁⨁ 
MODERATE  
Quality of Life (18 weeks) (assessed with: EORTC QLQ-C30) 
1  randomised 
trials  
not 
serious  
serious
1
 not  
serious  
not  
serious  
none  80/330 
(24.2%)  
52/335 
(15.5%)  
RR 1.56 
(1.14 to 
2.14)  
87 more per 1000 
(from 22 more to 177 
more)  
⨁⨁⨁ 
MODERATE  
Question: Ramucirumab+paclitaxel compared to placebo + paclitaxel for patients with gastric cancer or gastro-oesophageal junction adenocarcinoma 
Settings: after treatment with chemotherapy 
MD – mean difference, RR – relative risk  
1
 Single study, thus results not confirmed/shown consistently across different studies 
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Table 8: GRADE evidence profile for direct evidence and safety outcomes 
Quality assessment № of patients Effect 
Quality № of 
studies 
Study 
design 
Risk of 
bias Inconsistency Indirectness Imprecision 
Other 
considerations 
ramucirumab 
+ paclitaxel 
placebo + 
paclitaxel 
Relative 
(95%CI) 
Absolute 
(95%CI) 
Patients with one or more adverse events vs placebo+paclitaxel 
1  randomised 
trials 
not 
serious 
serious
1
 not  
serious 
not  
serious 
none 324/327 
(99.1%) 
322/329 
(97.9%) 
RR 1.01 
(0.99 to 1.03) 
10 more per 1000 
(from 10 fewer to 
29 more) 
⨁⨁⨁ 
MODERATE  
Patients with AE of grade 3 or higher 
1  randomised 
trials 
not 
serious 
serious
1
 not  
serious 
not  
serious 
none 267/327 
(81.7%) 
206/329 
(62.6%) 
RR 1.3 
(1.18 to 1.44) 
188 more per 1000 
(from 113 more to 
276 more) 
⨁⨁⨁ 
MODERATE 
Patients who discontinued treatment due to adverse events  
1  randomised 
trials 
not 
serious 
serious
1
 not  
serious 
serious
2
 none 38/335 
(11.3%) 
39/330 
(11.8%) 
RR 1.04 
(0.68 to 1.59) 
5 more per 1000 
(from 38 fewer to 
70 more) 
⨁⨁ 
LOW 
Patients with serious adverse event (Treatment-emergent SAE) 
1  randomised 
trials 
not 
serious 
serious
1
 not  
serious 
serious
2
 none 153/327 
(46.8%) 
139/329 
(42.2%) 
RR 1.11 
(0.93 to 1.31) 
46 more per 1000 
(from 30 fewer to 
131 more) 
⨁⨁ 
LOW 
Deaths due to an AE 
1  randomised 
trials 
not 
serious 
serious
1
 not  
serious 
serious
2
 none 13/327 (4.0%) 15/329 
(4.6%) 
RR 0.87 
(0.42 to 1.8) 
6 fewer per 1000 
(from 26 fewer to 
36 more) 
⨁⨁ 
LOW 
Question: Ramucirumab+paclitaxel compared to placebo + paclitaxel for patients with gastric cancer or gastro-oesophageal junction adenocarcinoma 
Settings: after treatment with chemotherapy  
MD – mean difference, RR – relative risk  
1
 Single study, thus results not confirmed/shown consistently across different studies 
2
 Confidence interval include both no difference and clear harm or benefit  
 
